Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,035.09 -9.59 (-0.92%)

Streaming Delayed Price Updated: 1:10 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

Today 13:20 EST

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Via The Motley Fool

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

Today 11:57 EST

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Via MarketMinute

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

Today 10:15 EST

Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...

Via Finterra

Topics Artificial Intelligence Economy Fraud

FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗

February 09, 2026

Via Chartmill

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

Today 9:59 EST

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Via Stocktwits

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)

Today 9:41 EST

Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. ↗

Today 9:35 EST

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Via The Motley Fool

Topics Intellectual Property

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

Today 4:10 EST

The stock has climbed in the triple digits over the past three years.

Via The Motley Fool

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

Via StockStory

Topics World Trade

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Via The Motley Fool

Topics Intellectual Property

Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried? ↗

February 09, 2026

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Via The Motley Fool

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

February 09, 2026

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

Via MarketMinute

Topics Intellectual Property Lawsuit

Why Eli Lilly Stock Just Popped ↗

February 09, 2026

Novo Nordisk just did Eli Lilly stock a huge favor.

Via The Motley Fool

Topics Lawsuit

Grounded in Reality or Echoes of '99? Merrill Strategists Say Today’s S&P 500 Is a Different Beast

February 09, 2026

As the S&P 500 (INDEXSP: .INX) pushes toward the 7,100 mark in early 2026, a growing chorus of investors is nervously glancing back at the ghosts of 1999. With the index having notched double-digit...

Via MarketMinute

Topics Artificial Intelligence Lawsuit Stocks

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

February 09, 2026

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Via MarketMinute

Topics Earnings Intellectual Property

The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value

February 09, 2026

On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently...

Via Finterra

Topics Earnings Economy Intellectual Property

Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments ↗

February 09, 2026

Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.

Via Benzinga

Monday's pre-market session: top gainers and losers in the S&P500 index ↗

February 09, 2026

Via Chartmill

LLY Stock Climbs Pre-Market On $2.4 Deal To Acquire Orna Therapeutics ↗

February 09, 2026

The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles.

Via Stocktwits

Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗

February 09, 2026

Via Chartmill

Topics Artificial Intelligence Stocks

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

Via Stocktwits

Topics Intellectual Property Law Enforcement

Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock? ↗

February 08, 2026

It doesn't look too late to buy the stock.

Via The Motley Fool

Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗

February 08, 2026

Retirees should brace themselves for both positive and negative changes to Medicare this year.

Via The Motley Fool

Topics Economy Government Retirement

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 07, 2026

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Via The Motley Fool

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

The most recent gold rush in weight loss drugs isn't done just yet.

Via The Motley Fool

Topics Economy

1 Brilliant Vanguard Index Fund to Buy Before It Soars 120%, According to a Wall Street Analyst ↗

February 07, 2026

Tom Lee says the S&P 500 (a benchmark for the U.S. stock market) can hit 15,000 by 2030.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

Via MarketMinute

Topics Earnings Economy

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have...

Via TokenRing AI

Topics Artificial Intelligence

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

Headline News about Eli Lilly

Starting at $3.75/week.

Subscribe Today